[go: up one dir, main page]

US20100280569A1 - Device and method for reducing weight - Google Patents

Device and method for reducing weight Download PDF

Info

Publication number
US20100280569A1
US20100280569A1 US12/675,194 US67519408A US2010280569A1 US 20100280569 A1 US20100280569 A1 US 20100280569A1 US 67519408 A US67519408 A US 67519408A US 2010280569 A1 US2010280569 A1 US 2010280569A1
Authority
US
United States
Prior art keywords
electrodes
generator
individual
vagus nerve
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/675,194
Other languages
English (en)
Inventor
Eric Bobillier
Charles-Henri Malbert
Arnaud Biraben
David Val-Laillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Centre Hospitalier Universitaire de Rennes
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES reassignment INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIRABEN, ARNAUD, BOBILLIER, ERIC, MALBERT, CHARLES-HENRI, VAL-LAILLET, DAVID
Publication of US20100280569A1 publication Critical patent/US20100280569A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114—Cardiac control, e.g. by vagal stimulation

Definitions

  • the invention relates to a method for reducing weight through vagus nerve stimulation and to a device for use in such treatment.
  • Obesity is one of the largest health problems in the western countries. It may lead to numerous secondary pathology, such as diabetes, sleep apnea, heart diseases, pulmonary diseases; osteoarthritis.
  • the aetiology of obesity is always multifactorial, including genetic and environmental factors. The ideal treatment of obesity is not yet available.
  • VNS Vagus Nerve Stimulation
  • WO 02/062291 describes a method and device for treating obesity in an individual through sub-diaphragmatic vagus nerve stimulation with an electrical pulse signal.
  • a device for reducing weight in an individual comprising a generator adapted to produce an electrical signal and at least a first set of electrodes comprising two electrodes able to be connected to the generator, the electrodes being intended to be fixed to a first vagus nerve of the individual at a predefined distance one from another, to apply the electrical signal to a portion of the first vagus nerve located between the electrodes.
  • the present invention relates to a device for reducing weight in an individual, the device comprising:
  • the present invention also relates to a device as defined above as a surgical implant for reducing weight in an individual.
  • the present invention also relates to a method for reducing weight in an individual, wherein an effective electrical signal is applied peri-diaphragmatically to a portion of a first vagus nerve and optionally to a portion of a second vagus nerve, wherein the electrical signal is in the form of pulses trains, the pulses having amplitudes increasing from 0.1 milliampere to 2.5 milliampere during a progressive phase (PP) and a constant amplitude equal to 2.5 milliampere during a stabilised phase (SP).
  • PP progressive phase
  • SP stabilised phase
  • the present invention further relates to a method for reducing weight in an individual, wherein an effective electrical signal is applied peri-diaphragmatically to a portion of a first vagus nerve and optionally to a portion of a second vagus nerve by at least one device as defined above.
  • the present invention also relates to the use of a device as defined above, for the manufacture of a surgical implant intended for reducing weight in an individual.
  • reducing weight in an individual relates to a reduction of the fat tissues of the individual.
  • the individual may or may not suffer from obesity. If the individual suffers from obesity, in particular from morbid obesity, then the method amounts to a method for treating obesity. This expression also encompasses a reduction in weight increase.
  • “obesity” relates to a condition characterized by an excess body weight of an individual with respect to the individual's size, as compared to a normal individual.
  • BMI Body Mass Index
  • Individuals with a BMI of 35-40 of greater will be said to be severely obese or morbidly obese.
  • the device, methods and use according to the invention can be applied to any individual whose body weight, in particular fat body weight, needs to be reduced, be he considered obese or non-obese.
  • the methods of the invention should not be considered as therapeutic methods but merely as non-therapeutic methods or aesthetic methods.
  • weight-related diseases or obesity-related pathologies relates to pathologies which aetiologies comprise excess weight or obesity. Such pathologies may notably encompass type 2 diabetes, sleep apnea, heart diseases, pulmonary diseases, or osteoarthritis.
  • “individual” preferably relates to a mammal, in particular a human.
  • vagus nerve designates the cranial nerve X and its various branches.
  • the “first vagus nerve” and the “second vagus nerve” are selected from the ventral vagus nerve (which innervates in part the stomach, the liver and the proximal duodenum) and the dorsal vagus nerve (which innervates in part the stomach and gets lost in the celiac ganglia).
  • an effective electrical signal is applied to both the first and second vagus nerves
  • peripherally designates a portion of the vagus nerve which is located next to the diaphragm, either supra-diaphragmatically or sub-diaphragmatically.
  • this portion is located from 1 cm to 2 cm below diaphragm level for the sub-diaphragm position. This position corresponds to a part of the vagus nerve which can be easily freed from connective tissues.
  • the portion is preferably from 1 cm to 2 cm above the diaphragm. This position corresponds to the part of the vagus nerve located immediately above the Plexus gastricus cranialis.
  • the expression “effective electric signal” relates to a signal which characteristics (such as intensity, amplitude, pulse duration, frequency) enable a reduction of body weight or of body weight increase.
  • the surgical methodology for implanting the device according to the invention or for vagus nerve stimulation is well known to one of skill in the art and may follow that described e.g. by S. A. Reid (“Surgical technique for implantation of the neurocybernetic prothesis.” Epilepsia 31:S38-S39, 1990) for epilepsy treatment.
  • the device is implanted in a left subclavian area of the individual.
  • FIG. 1 is a simplified partial front view of a mammal body and of the medical device according to the invention
  • FIG. 2 is a block diagram of the medical device according to the invention.
  • FIG. 3 is a schematic timing chart illustrating a progressive phase and a stabilised phase generated by the medical device according to the invention
  • FIG. 4 is a schematic timing chart illustrating the pulses trains transmitted to channels A and B during the stabilised phase
  • FIG. 5 is a schematic timing chart illustrating two pulses of a pulse train
  • the body weight of vagal stimulated animals is significantly different from the sham ones at week 6 and after;
  • FIG. 7 represents the mean difference in food intake in the sham (dashed boxes) and vagal stimulated (black boxes) animals of Example 4. Except for one week, the daily consumption of stimulated animals is always less than the reference level.
  • the medical device 2 is a vagus electro-stimulator device. It comprises an electronic unit 4 , a first 6 and second 8 sets of insulated electrodes/leads connected to the electronic unit 4 .
  • the two sets of electrodes 6 , 8 are connected to a single electronic unit 4 included in a box.
  • the box is made of titanium.
  • the box is surgically implanted in a subcutaneous pocket of a left subclavian area of the individual.
  • the first set 6 comprises a first 10 and a second 12 electrodes having distal ends respectively 14 and 16 .
  • the distal ends 14 and 16 are intended to be fixed to the dorsal vagus nerve 18 at a predefined distance one from another to apply a current signal to a portion 19 of the dorsal vagus nerve 18 located between these distal ends.
  • the proximal ends of the first set 6 are linked to output connectors 20 , 22 of the electronic unit 4 .
  • the second set 8 comprises a first 24 and a second 26 electrodes having distal ends respectively 28 and 30 intended to be fixed to a ventral vagus nerve 32 at a predefined distance one from another to apply the current signal to a portion 33 of the ventral vagus nerve 32 located between these distal ends.
  • the proximal ends of the second set 8 are connected to output connectors 34 , 36 of the electronic unit 4 .
  • the distal ends 14 , 16 , 28 , 30 of the electrodes are positioned in an area between the top part of the stomach 38 and the lower part of the diaphragm 40 .
  • the electrodes 10 , 12 , 24 , 26 are placed surgically using minimal invasive procedure for the nerves shield surrounding the dorsal and the ventral vagus nerves either immediately before or after the diaphragm 40 .
  • the electronic unit 4 comprises a voltage generator 42 , a voltage current converter 43 , a digital-to-analogue converter 44 and a microprocessor 46 connected to the digital-to-analogue converter 44 .
  • the voltage generator 42 is a rechargeable battery.
  • the voltage current converter 43 comprises a transistor 45 adapted to be linked to the voltage generator 42 , an amplifier 47 connected to the transistor 45 and a resistance 49 connected to the transistor 45 .
  • the transistor 45 is an n-channel Bipolar Junction Transistor (BJT). It has a base connected to the output of the amplifier 47 via a resistance 82 , an emitter linked to the resistance 49 , and a collector adapted to be connected to one terminal of the voltage generator 42 , the other terminal of the voltage generator being connected to a ground 53 .
  • BJT Bipolar Junction Transistor
  • the amplifier 47 has a negative input connected by a line 55 to the resistance 49 and to the emitter of the transistor 45 , and a positive input linked to the digital-to-analogue converter 44 .
  • the voltage current converter 43 comprises a terminal 51 linked to the resistance 49 .
  • the terminal 51 is set at a predetermined positive voltage of 1.5 V.
  • the voltage current converter 43 operates as well known in the state of the art.
  • the voltage generator 42 and the voltage current converter form a current generator hereafter referenced 42 , 43 .
  • the current generator 42 , 43 is adapted to apply a current signal to the portion 19 of the dorsal vagus nerve 18 and to the portion 33 of the vagus nerve 32 .
  • the portions of the vagus nerves 19 , 33 located between the distal ends 14 , 16 and 28 , 30 constitute a load for the current generator 42 , 43 .
  • This load can vary along the time.
  • the current generator 42 , 43 is able to adapt the voltage applied to the portions 19 and 33 of the vagus nerves (i.e. load) such as to maintain the amplitude of the current signal approximately constant between the distal ends 14 , 16 of the first set and between the distal ends 28 , 30 of the second set.
  • the digital-to-analogue converter 44 is adapted to convert the digital commands of the microcontroller 46 into analogue ones, as well known.
  • the microprocessor 46 comprises a memory 48 which stores a computer programme defining the current supply commands to the current generator 42 , 43 .
  • the microprocessor 46 is able to transmit these commands to the amplifier 47 via the digital-to-analogue converter 44 .
  • the electronic unit 4 also comprises an RF emitter/receiver 49 to send and receive data to and from a handheld programming device, e.g. to amend the computer programme stored in the memory 48 .
  • the electronic unit 4 further comprises a channel selector switch 50 connected to the voltage generator 42 , to the terminal 51 and to the microprocessor 46 ; a short-circuiting switch 52 linked to the channel selector switch 50 and to the output connectors 20 , 22 , 34 , 36 ; and a no compliance detector 54 connected to the microprocessor 46 , to the voltage generator 42 and to the terminal 51 .
  • the channel selector switch 50 comprises an input 56 for receiving the current signal of the current generator 42 , 43 , an output 57 connected to the collector of the transistor 45 , two lines 58 , 60 connected to the output connectors 20 and 22 for current supplying the dorsal vagus nerve 18 , and two lines 62 , 64 connected to the output connectors 34 and 36 for current supplying the ventral vagus nerve 32 .
  • the channel selector switch 50 further comprises two resistances having high impedance and not illustrated in FIG. 2 .
  • the channel selector switch 50 is adapted to connect alternatively the input 56 and the output 57 to the lines 58 , 60 , to the lines 62 , 64 and to the resistances according to the commands received from the microcontroller 46 .
  • the channel selector switch 50 has two contacts not illustrated which are able to select three different electrical terminals noted 1 , 2 and 3 .
  • the current generator 42 , 43 is linked to the resistances. This corresponds to a high impedance connection.
  • the current generator 42 , 43 is linked to the lines 58 and 60 .
  • the electrodes 10 and 12 supply a current signal to the portion 19 of the dorsal vagus nerve.
  • the current generator 42 , 43 is linked to the lines 62 and 64 .
  • the electrodes 24 and 26 supply a current signal to the portion 33 of the ventral vagus nerve.
  • the microcontroller 46 is adapted to control the channel selector switch 50 such that the current signal is supplied to the electrodes 10 , 12 and the electrodes 24 , 26 only during specific periods as described hereafter.
  • the short-circuit switch 52 comprises a first n channel MOSFET transistor 66 in depletion mode, a second n channel MOSFET transistor 68 in depletion mode.
  • the first MOSFET transistor 66 has a gate D connected to the output line 58 , a source S connected to the output line 60 and a gate connected to a ground 70 through a line 72 .
  • the second MOSFET transistor 68 has a gate D connected to the output line 62 , a source S connected to the output line 64 and a gate connected to the ground 70 through the line 72 .
  • Each transistor 66 , 68 is configured so that when the potential difference (voltage) between its gate and its source is lower than a predefined threshold, the transistor 66 , 68 is turned on, namely the transistor 66 , 68 is in a passing current status.
  • the two electrodes 10 , 12 (or the electrodes 24 , 26 ) are short-circuited.
  • the transistor 66 , 68 When the potential difference between its gate and its source is greater than this predefined threshold, the transistor 66 , 68 is turned off. There is an open circuit between the two electrodes 10 , 12 (or the electrodes 24 , 26 ).
  • the no compliance detector 54 comprises a first 76 and a second 78 transistors. These transistors are n-channel Bipolar Junction Transistors (BJT).
  • BJT Bipolar Junction Transistors
  • the first transistor 76 is a pnp transistor. It comprises an emitter connected to the output of the amplifier 47 and to the base of the transistor 45 via the resistance 82 , a base linked to the base of the transistor 45 via a resistance 84 , and a collector connected to the base of the second transistor 78 through a resistance 86 .
  • the second transistor 78 comprises a base, an emitter connected to the ground 87 , and a collector connected to the microprocessor 46 and to a voltage source 88 through a resistance 90 .
  • the current generator 42 , 43 attempts to compensate this insufficiency by increasing the current signal circulating from the base to the collector of the transistor 45 .
  • the voltage between the terminals of the resistance 82 increases and the current signal passing through the collector and the emitter of the first transistor 76 increases.
  • the current signal delivered by the base of the second transistor 78 increases causing a current signal to be transmitted from the voltage source 88 to the ground 87 .
  • the microcontroller 46 is adapted to detect the appearance of this current signal and to generate an alarm. This alarm reflects the fact that the electronic unit 4 is operating under non compliance conditions i.e a current signal having a abnormal elevated amplitude is delivered to the vagus nerves. The alarm can also be generated when one of the electrodes 8 , 10 , 24 , 26 is cut.
  • the invention also concerns a method for reducing weight wherein an effective current signal is delivered to the vagus nerves along time according to a predefined method which is implemented in the computer program stored in the memory 48 .
  • the amplitude of the current signal applied to the mammal body increases gradually during an initial phase, hereafter named progressive phase PP, and is maintained constant during a permanent phase, hereafter named stabilised phase SP, illustrated in FIG. 3 .
  • the progressive phase PP lasts between 10 and 20 days during which the amplitude increases from 0.1 milliampere to 2.5 milliampere.
  • the progressive phase PP lasts 15 days during which the amplitude increases from 0.1 milliampere to 2.5 milliampere so that the amplitude of the current signal increases each day from 0.16 milliampere.
  • the stabilised phase SP is preferably maintained until treatment of the individual interrupted.
  • the amplitude of the current signal is maintained equal to 2.5 milliampere during the stabilised phase SP.
  • the progressive phase PP and the stabilised phase SP comprise emission periods T 1 which last each 30 seconds and non emission periods T 2 which last each 5 minutes.
  • the contacts of the selector switch 50 switch from terminal 2 to terminal 3 at a frequency of 60 Hz.
  • the current signal generator 42 , 43 provides current signal alternatively to the electrodes 10 , 12 (channel A in FIG. 4 ) and to the electrodes 24 , 26 (channel B in FIG. 4 ).
  • the gate of transistor 66 , 68 is linked to the voltage generator 42 and the source of this transistor is linked the terminal 51 , the potential difference between the gate and the source of this transistor is greater than the predetermined threshold.
  • the transistor 66 , 68 is turned off.
  • the electrodes 10 and 12 are not short-circuited.
  • the current generator 42 , 43 connected to a single battery provides current to both channel A via the first set of electrodes 6 and to channel B via the second set of electrodes 8 . Consequently, a pulse is never simultaneously delivered to both vagus nerves, as schematically illustrated with dotted lines in FIG. 4 .
  • the dorsal 18 and the ventral 32 vagus nerves are never stimulated simultaneously but one after another such that no linkage current appears between the portion 19 of the dorsal vagus nerve 18 and the portion 33 of the ventral vagus nerve 32 .
  • linkage current signals are damageable. They appear when the impedance of the portion 19 of the dorsal vagus nerve is different from the impedance of the portion 33 of ventral vagus nerve. In this case, a potential difference appears between the portion 19 of the dorsal vagus nerves and the portion 33 of the ventral vagus resulting in the emergence of a current between the dorsal vagus nerve and the ventral vagus nerve.
  • the current signal generated during the emission period T 1 is formed of pulses trains, as schematically illustrated in FIG. 4 .
  • An enlarge view of two consecutive pulses is illustrated in FIG. 5 .
  • the duration L of each pulse is equal to 1 millisecond.
  • the duty cycle of one period of the current signal is equal to 1/30.
  • the period P defined between two consecutive pulses is equal to 33 milliseconds.
  • the contacts of the selector switch 50 are connected to the terminal 1 .
  • No current signal is provided to the electrodes 10 , 12 or to the electrodes 24 , 26 .
  • the device according to the invention avoids the appearance of linkage currents between nerves connected to a stimulation device, when the device does not stimulate these nerves.
  • the described embodiment of the invention needs less energy because the non emission periods T 2 are longer than the emission periods T 1 .
  • classical MOSFET transistor can also be used in the short-circuit switch 52 .
  • the device can be implemented with a voltage generator instead of the current generator 42 , 43 .
  • a voltage signal is applied to the vagus nerves.
  • the device as defined above is a single-use device.
  • a single-use device is a device which can only be implanted once, i.e. the device can not be implanted in a second individual after it has been implanted in a first individual.
  • surgical implants are generally only proper for a single use because they may have been damaged or worn during their implantation period in the first individual (i.e. the surgical implants have been consumed by their use) or because they have been in contact with tissues or fluids of the first individual, which renders their use in a second individual hazardous due to possible contaminations.
  • VNS group Vagal Nerve Stimulation
  • Sham group One group of pigs without VNS, having the same surgical procedure.
  • the pigs were large white females about 3 months old and 35 kg weigh at the beginning of the experiment.
  • Surgery was performed under general anaesthesia, after a few days of acclimatization of the animals to their cage.
  • the electrodes were implanted immediately above the diaphragm. The stimulation was applied bilaterally on the ventral and dorsal vagus nerves. Electrodes implantation with bipolar leads required a thoracotomy with the ablation of the left 8 th cost; both of the bipolar VNS leads (Cyberonics) were coupled with a device according to the invention.
  • each animal had a week for recovering, followed by a week of measures without stimulation. Stimulation was then started in the stimulated group.
  • the parameters of stimulation with the exception of output current intensity were kept unchanged during the entire duration of the experiment (frequency of pulses within the trains, 30 Hz; pulse duration, 1 ms; duration of the train, 30 seconds; and frequency of the trains, 300 s). These values are similar to those usually used in human for epilepsy treatment.
  • the output current intensity was increased gradually starting at 0.25 mA and ending at 2.5 mA, so that the amplitude increased of 0.16 mA each day.
  • the animals were fed once every day at the same time and in the same conditions. Access to food was ad libitum for half an hour; the quantity of food (2.2 kg) provided was more than the maximal usual ration for pigs of this age and size. The changes in the weight of the pigs were measured as well as other parameters measured on line during the meal, using a weight gauge located under the animal trough: amounts of food consumed at 10 minutes, 20 minutes and 30 minutes and the ingestion speed.
  • VNS group Nerve Stimulation
  • 4 pigs without VNS having the same surgical procedure.
  • These animals were different from those used for Example 1.
  • the surgical preparation and vagal nerve stimulation procedure were identical to that previously described
  • the animals were feed three times daily (9H30, 12H00 and 16H30) for 30 minutes each.
  • the animal has access to three different meals presented in three troughs randomly selected by a dedicated robotic device. This device supplies exactly 600 g of food in each trough so that for each individual meal the animal has the possibility to eat up to 1800 g.
  • the meals were different in their composition: one being identical to standard pig food (Control), the other being enriched in sucrose and the last one being enriched with animal and vegetal fat.
  • the composition of each meal is summarized in Table 2.
  • Vagal nerve stimulation was effective to reduce food intake. However, this might be the result of a slow down in gastric emptying. This reduced emptying in turn is able to induce an increased sensation of fullness which is known to reduce ingestion. This, if it is true, will be damageable to the proposed device and method because in human's gastric stasis aside from being capable to reduce food intake generates epigastric fullness and pain. Therefore, the inventors aimed at demonstrating that the proposed device and method were able to reduce food intake without altering the normal gastric emptying process.
  • VNS group Vagal Nerve Stimulation
  • VNS group Vagal Nerve Stimulation
  • 4 pigs without VNS having the same surgical procedure. These animals were different from those used for Examples 1 and 2. However, the surgical preparation and vagal nerve stimulation procedure were identical to that previously described.
  • the inventors have designed another experiment involving (1) adult animals instead of pre-pubertal ones and (2) obese animals instead of lean ones. Furthermore, vagal stimulation and surgery were performed in morbidly obese animals to be as close as possible to the pathological setting of the human patients the device and method of the invention can be applied to.
  • Two groups of four miniature pigs (Gottingen mini-pigs, 41.9 ⁇ 1.3 kg initially, 18 months at the beginning of the experiment) were feed ad libitum with a western diet supplying energy in excess by 2.5 times the normal requirement during 4 months. After this period, the animals weighted 66.2 ⁇ 4.8 kg and were in a morbid obese state as indicated by insulin and glycemia concentrations.
  • Example 1 Once in a morbid obese situation, four animals were fitted with dual vagal electrodes as indicated in Example 1 connected to two devices according to the invention placed under the skin. The four remaining animals received a sham surgery and two mock devices of the same size and weight as the workings ones were also placed under the skin.
  • Example 1 One week after surgery, the devices were powered on as indicated in Example 1. During 15 weeks, the weight and diet consumption of the animals were monitored. The animals received the same western diet ad libitum as before during this experimental period.
  • vagal stimulation are statistically different between the groups 6 weeks after the onset of neurostimulation ( FIG. 6 ).
  • the weight difference between the two groups is getting more important along the time course of stimulation.
  • the sham group weights more than their reference weight defined as the weight at week zero (p ⁇ 0.05). This effect does not vanish during the entire experimental period which lasts 15 weeks.
  • vagal stimulated group is less than control group starting at week 2 after the onset of the neurostimulation (p ⁇ 0.05, FIG. 7 ). This effect does not vanish during the entire experimental period which lasts 15 weeks.
  • VNS Vagal Nerve Stimulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrotherapy Devices (AREA)
US12/675,194 2007-08-28 2008-08-27 Device and method for reducing weight Abandoned US20100280569A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2007/002466 WO2009027755A1 (fr) 2007-08-28 2007-08-28 Dispositif et procédé de réduction de poids
IBPCT/IB2007/002466 2007-08-28
PCT/EP2008/061204 WO2009027425A2 (fr) 2007-08-28 2008-08-27 Dispositif et procédé de réduction de poids

Publications (1)

Publication Number Publication Date
US20100280569A1 true US20100280569A1 (en) 2010-11-04

Family

ID=38924599

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/675,194 Abandoned US20100280569A1 (en) 2007-08-28 2008-08-27 Device and method for reducing weight

Country Status (10)

Country Link
US (1) US20100280569A1 (fr)
EP (1) EP2185235B1 (fr)
JP (2) JP5693225B2 (fr)
AU (1) AU2008292174B2 (fr)
CA (1) CA2697622C (fr)
DK (1) DK2185235T3 (fr)
IL (1) IL204110A (fr)
NZ (1) NZ583619A (fr)
WO (2) WO2009027755A1 (fr)
ZA (1) ZA201001287B (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062874A1 (en) * 2007-08-27 2009-03-05 Tracey Kevin J Devices and methods for inhibiting granulocyte activation by neural stimulation
US20110106208A1 (en) * 2009-10-30 2011-05-05 Faltys Michael A Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
WO2016046766A1 (fr) * 2014-09-23 2016-03-31 Inria Institut National De Recherche En Informatique Et En Automatique Procédé et dispositif de stimulation de neurones vagaux de petit diamètre myélinisé et non myélinisé
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2025136970A1 (fr) * 2023-12-20 2025-06-26 Boomerang Medical, Inc. Systèmes et procédés permettant d'ajuster automatiquement et/ou de manière incrémentielle un ou plusieurs paramètres d'administration de signal pour une neuromodulation sacrée
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5816408B2 (ja) * 2009-11-13 2015-11-18 オリンパス株式会社 神経刺激装置

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408608A (en) * 1981-04-09 1983-10-11 Telectronics Pty. Ltd. Implantable tissue-stimulating prosthesis
US5314457A (en) * 1993-04-08 1994-05-24 Jeutter Dean C Regenerative electrical
US20020087192A1 (en) * 2001-01-02 2002-07-04 Barrett Burke T. Treatment of obesity by sub-diaphragmatic nerve stimulation
US6611715B1 (en) * 1998-10-26 2003-08-26 Birinder R. Boveja Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator
US20040024428A1 (en) * 1999-07-01 2004-02-05 Burke Barrett Treatment of obesity by bilateral vagus nerve stimulation
US20040199210A1 (en) * 2002-06-12 2004-10-07 Shelchuk Anne M. Vagal stimulation for improving cardiac function in heart failure or CHF patients
US20040230255A1 (en) * 2002-03-22 2004-11-18 Dobak John D. Splanchnic nerve stimulation for treatment of obesity
US20040267344A1 (en) * 2001-10-17 2004-12-30 Alfred Stett Electrode arrangement for electrical stimulation of biological material, and a multi-electrode array for use in such an electrode arrangement
US20050021101A1 (en) * 2000-04-11 2005-01-27 Jiande Chen Gastrointestinal electrical stimulation
US6853858B2 (en) * 2000-05-08 2005-02-08 Brainsgate, Ltd. Administration of anti-inflammatory drugs into the central nervous system
US20050049655A1 (en) * 2003-08-27 2005-03-03 Boveja Birinder R. System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities
US20050137644A1 (en) * 1998-10-26 2005-06-23 Boveja Birinder R. Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders
US20050143787A1 (en) * 2002-05-09 2005-06-30 Boveja Birinder R. Method and system for providing electrical pulses for neuromodulation of vagus nerve(s), using rechargeable implanted pulse generator
US20050197675A1 (en) * 2001-08-31 2005-09-08 Biocontrol Medical Ltd. Techniques for applying, calibrating, and controlling nerve fiber stimulation
US20060167512A1 (en) * 2005-01-21 2006-07-27 Virginia Technologies, Inc. Energy efficient therapeutic pulse generator system
US20060190053A1 (en) * 2002-03-22 2006-08-24 Dobak John D Iii Neural stimulation for treatment of metabolic syndrome and type 2 diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7689276B2 (en) * 2002-09-13 2010-03-30 Leptos Biomedical, Inc. Dynamic nerve stimulation for treatment of disorders
WO2004044947A2 (fr) * 2002-11-14 2004-05-27 Brainsgate Ltd. Circuits de stimulation et commande d'un dispositif medical electronique
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408608A (en) * 1981-04-09 1983-10-11 Telectronics Pty. Ltd. Implantable tissue-stimulating prosthesis
US5314457A (en) * 1993-04-08 1994-05-24 Jeutter Dean C Regenerative electrical
US20050137644A1 (en) * 1998-10-26 2005-06-23 Boveja Birinder R. Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders
US6611715B1 (en) * 1998-10-26 2003-08-26 Birinder R. Boveja Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator
US20040024428A1 (en) * 1999-07-01 2004-02-05 Burke Barrett Treatment of obesity by bilateral vagus nerve stimulation
US20050021101A1 (en) * 2000-04-11 2005-01-27 Jiande Chen Gastrointestinal electrical stimulation
US6853858B2 (en) * 2000-05-08 2005-02-08 Brainsgate, Ltd. Administration of anti-inflammatory drugs into the central nervous system
US20020087192A1 (en) * 2001-01-02 2002-07-04 Barrett Burke T. Treatment of obesity by sub-diaphragmatic nerve stimulation
US6609025B2 (en) * 2001-01-02 2003-08-19 Cyberonics, Inc. Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation
US20040039427A1 (en) * 2001-01-02 2004-02-26 Cyberonics, Inc. Treatment of obesity by sub-diaphragmatic nerve stimulation
US20050197675A1 (en) * 2001-08-31 2005-09-08 Biocontrol Medical Ltd. Techniques for applying, calibrating, and controlling nerve fiber stimulation
US20040267344A1 (en) * 2001-10-17 2004-12-30 Alfred Stett Electrode arrangement for electrical stimulation of biological material, and a multi-electrode array for use in such an electrode arrangement
US20040230255A1 (en) * 2002-03-22 2004-11-18 Dobak John D. Splanchnic nerve stimulation for treatment of obesity
US20060190053A1 (en) * 2002-03-22 2006-08-24 Dobak John D Iii Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US20050143787A1 (en) * 2002-05-09 2005-06-30 Boveja Birinder R. Method and system for providing electrical pulses for neuromodulation of vagus nerve(s), using rechargeable implanted pulse generator
US20040199210A1 (en) * 2002-06-12 2004-10-07 Shelchuk Anne M. Vagal stimulation for improving cardiac function in heart failure or CHF patients
US20050049655A1 (en) * 2003-08-27 2005-03-03 Boveja Birinder R. System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities
US20060167512A1 (en) * 2005-01-21 2006-07-27 Virginia Technologies, Inc. Energy efficient therapeutic pulse generator system

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20090062874A1 (en) * 2007-08-27 2009-03-05 Tracey Kevin J Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9849286B2 (en) 2009-05-01 2017-12-26 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US10220203B2 (en) 2009-06-09 2019-03-05 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US12251558B2 (en) 2009-06-09 2025-03-18 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US10716936B2 (en) 2009-06-09 2020-07-21 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9174041B2 (en) 2009-06-09 2015-11-03 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9700716B2 (en) 2009-06-09 2017-07-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US20110106208A1 (en) * 2009-10-30 2011-05-05 Faltys Michael A Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US12290695B2 (en) 2009-12-23 2025-05-06 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9993651B2 (en) 2009-12-23 2018-06-12 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US10384068B2 (en) 2009-12-23 2019-08-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8855767B2 (en) 2009-12-23 2014-10-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US11110287B2 (en) 2009-12-23 2021-09-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9162064B2 (en) 2009-12-23 2015-10-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12357826B2 (en) 2011-05-09 2025-07-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US10449358B2 (en) 2012-03-26 2019-10-22 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11969253B2 (en) 2013-04-10 2024-04-30 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US12402826B2 (en) 2013-04-10 2025-09-02 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
WO2016046766A1 (fr) * 2014-09-23 2016-03-31 Inria Institut National De Recherche En Informatique Et En Automatique Procédé et dispositif de stimulation de neurones vagaux de petit diamètre myélinisé et non myélinisé
WO2016046587A1 (fr) * 2014-09-23 2016-03-31 Inria Institut National De Recherche En Informatique Et En Automatique Procédé et dispositif pour la stimulation de neurones vagaux de petit diamètre myélinisés et non myélinisés
US12383741B2 (en) 2014-10-24 2025-08-12 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11278718B2 (en) 2016-01-13 2022-03-22 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US12296169B2 (en) 2016-01-20 2025-05-13 Setpoint Medical Corporation Batteryless implantable microstimulators
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US11964150B2 (en) 2016-01-20 2024-04-23 Setpoint Medical Corporation Batteryless implantable microstimulators
US11547852B2 (en) 2016-01-20 2023-01-10 Setpoint Medical Corporation Control of vagal stimulation
US12121726B2 (en) 2016-01-20 2024-10-22 Setpoint Medical Corporation Control of vagal stimulation
US11383091B2 (en) 2016-01-25 2022-07-12 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US12472368B2 (en) 2016-01-25 2025-11-18 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11890471B2 (en) 2017-08-14 2024-02-06 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11857788B2 (en) 2018-09-25 2024-01-02 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12220579B2 (en) 2018-09-25 2025-02-11 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12465768B2 (en) 2020-05-21 2025-11-11 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
WO2025136970A1 (fr) * 2023-12-20 2025-06-26 Boomerang Medical, Inc. Systèmes et procédés permettant d'ajuster automatiquement et/ou de manière incrémentielle un ou plusieurs paramètres d'administration de signal pour une neuromodulation sacrée

Also Published As

Publication number Publication date
CA2697622C (fr) 2017-08-01
WO2009027425A3 (fr) 2009-04-16
DK2185235T3 (en) 2016-06-20
NZ583619A (en) 2011-12-22
ZA201001287B (en) 2010-12-29
AU2008292174A2 (en) 2010-04-29
EP2185235A2 (fr) 2010-05-19
AU2008292174B2 (en) 2013-11-07
IL204110A (en) 2013-05-30
JP2010536523A (ja) 2010-12-02
WO2009027755A1 (fr) 2009-03-05
JP2015006439A (ja) 2015-01-15
WO2009027425A2 (fr) 2009-03-05
EP2185235B1 (fr) 2016-03-16
JP5693225B2 (ja) 2015-04-01
CA2697622A1 (fr) 2009-03-05
AU2008292174A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
CA2697622C (fr) Dispositif et procede de reduction de poids
US7299091B2 (en) Treatment of obesity by bilateral vagus nerve stimulation
US8321030B2 (en) Esophageal activity modulated obesity therapy
US7689276B2 (en) Dynamic nerve stimulation for treatment of disorders
US7844338B2 (en) High frequency obesity treatment
US8538532B2 (en) Electrical stimulation therapy to promote gastric distention for obesity management
US9037244B2 (en) Method and apparatus for electrical stimulation of the pancreatico-biliary system
US7613515B2 (en) High frequency vagal blockage therapy
US7236822B2 (en) Wireless electric modulation of sympathetic nervous system
US7551964B2 (en) Splanchnic nerve stimulation for treatment of obesity
US20100145408A1 (en) Splanchnic Nerve Stimulation For Treatment of Obesity
US20100241189A1 (en) Nerve Stimulation For Treatment of Obesity, Metabolic Syndrome, and Type 2 Diabetes
US20130041424A1 (en) Duodenal stimulation to induce satiety
AU782785B2 (en) Treatment of obesity by bilateral vagus nerve stimulation
WO2009020581A1 (fr) Stimulation nerveuse splanchnique efférente et afférente
EP1984067A2 (fr) Neurostimulation pour traiter l'obésité, le diabète de type 2 et le syndrome métabolique
AU2004216247A1 (en) Splanchnic nerve stimulation for treatment of obesity

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOBILLIER, ERIC;MALBERT, CHARLES-HENRI;BIRABEN, ARNAUD;AND OTHERS;REEL/FRAME:024610/0368

Effective date: 20100609

Owner name: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOBILLIER, ERIC;MALBERT, CHARLES-HENRI;BIRABEN, ARNAUD;AND OTHERS;REEL/FRAME:024610/0368

Effective date: 20100609

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION